Migraine and psychiatric comorbidity: From theory and hypotheses to clinical application

Headache

Volumn 42, Issue 9, 2002, Pages 934-944

  Sheftell, Fred D ^a   Atlas, Susan J ^a  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

Anxiety; Behavioral medicine; Depression; Migraine; Substance overuse and misuse

Indexed keywords

AMFEBUTAMONE; DOPAMINE RECEPTOR BLOCKING AGENT; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; ANXIETY DISORDER; BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG USE; ENVIRONMENTAL FACTOR; GENETIC RISK; HEAD INJURY; HUMAN; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; PATHOPHYSIOLOGY; PATIENT EDUCATION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SUPPORT GROUP; TRAUMATIC EPILEPSY;

ANXIETY DISORDERS; BEHAVIORAL MEDICINE; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; MIGRAINE DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 0036803539     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2002.02217.x     Document Type: Review

References (49)

1. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994;44:S4-S5.
2. American Psychiatric Association. Work Group on DSM-IV-PC, American Academy of Family Physicians. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Primary Care Version, 1st Ed. Washington, DC: American Psychiatric Association; 1995.
3. Feldman MD. Munchausen by Internet: Detecting factitious illness and crisis on the Internet. South Med J. 2000;93:669-672.
4. Adler A. Understanding Human Nature. New York: Greenberg; 1927.
5. Selye H. The Stress of Life. Rev. Ed. New York: McGraw-Hill; 1978.
6. Cannon WB. The Wisdom of the Body. New York: W. W. Norton & Company; 1939:xviii, 19-333.
7. Bernard C. An Introduction to the Study of Experimental Medicine. Mineola, NY: Dover Publications; 1927.
8. Pavlov IP. Experimental Psychology, and Other Essays. New York: Philosophical Library; 1957.
9. Alexander F, Benedek T. Psychosomatic Medicine, Its Principles and Applications, 1st Ed. New York: Norton; 1950.
10. Wolff HG. Headache and Other Head Pain, 2nd Ed. New York: Oxford University Press; 1963.
11. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults. Psych Res. 1991;37:11-23.
12. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: Is the association specific to migraine? Neurology. 2000;54:308-313.
13. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psych. 1994;51:8-19.
14. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry. 1994; 151:979-986.
15. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
16. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: A neglected major illness. J Clin Psych. 1993;54:419-424.
17. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psych. 1993;54:405-418.
18. Agency for Health Care Policy and Research. Depression in Primary Care. Vol. 2. Treatment of Major Depression. Rockville, MD: AHCPR; 1993.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6:278-296.
20. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
21. Beck AT, Beamesderfer A. Assessment of depression: The depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151-169.
22. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272:1749-1756.
23. Greene RL. MMPI-2: An Interpretive Mannual, 2nd Ed. Needham Heights, MA: Allyn & Bacon; 1999.
24. Krishnan K. Depression as a contributing factor to cardiovascular disease [abstract]. Am Heart J. 2000; 140:70-76.
25. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: A population-based case-control study. Neurology. 2000;55:629-635.
26. Dubovsky SL. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. J Clin Psychiatry. 1994;55(suppl): 34-44.
27. Marcus DA. Serotonin and its role in headache pathogenesis and treatment. Clin J Pain. 1993;9: 159-167.
28. Goadsby PJ. The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci. 1999;26(suppl 3):S20-S26.
29. Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol. 2000;15:171-181.
30. Peroutka SJ. Dopamine and migraine. Neurology. 1997;49:650-656.
31. Barbanti P, Fabbrini G, Ricci A, et al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia. 2000;20:15-19.
32. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics. 2000;3:35-40.
33. Seligman MEP. Helplessness: On Depression, Development and Death. San Francisco: W. H. Freeman and Company; 1975.
34. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
35. Advisory Committee of the Primary Care Network. Patient-Centered Strategies for Effective Management of Migraine. Springfield, MO: PCN; 2000. www.primarycarenet.org/pcs
36. Coyne JC, Pepper CM, Flynn H. Significance of prior episodes of depression in two patient populations. J Consult Clin Psychol. 1999;67:76-81.
37. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 1998;7:443-449.
38. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians. Can J Psychiatry. 2000;45:476-481.
39. Pinsker W. Potentially safe and effective new treatment for migraine? Headache. 1993;33:163.
40. Kaniecki RG. Nefazodone in the prophylaxis of migraine: A prospective open label trial [poster 42]. Presented at the 40th Annual Scientific Meeting The American Association for the Study of Headache, San Francisco, Calif., June 26-28, 1998.
41. Davidoff RA. Migraine: Manifestation, Pathogenesis, and Management. Philadelphia, PA: F. A. Davis; 1995.
42. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000;40:572-580.
43. Slaby AE, Tancredi LR. Micropharmacology: Treating disturbances of mood, thought, and behavior as specific neurotransmitter dysregulations rather than as clinical syndromes. Prim Psych. 2001;8:28-32.
44. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry. 1994;151:413-420.
45. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psych. 1989;46:984-992.
46. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995;49:328-344.
47. Saper J, Sheftell F. Headache in the abuse-prone individual. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000:953-958.
48. Martin NJ, Holroyd KA, Penzien DB. The headache-specific locus of control scale: Adaptation to recurrent headaches. Headache. 1990;30:729-374.
49. French DJ, Holroyd KA, Pinell C, Malinoski PT, O'Donnell F, Hill KR. Perceived self-efficacy and headache-related disability. Headache. 2000;40:647-656.